dc.contributor
Universitat Ramon Llull. IQS
dc.contributor.author
Nadal-Gratacós, Núria
dc.contributor.author
Mata, Sandra
dc.contributor.author
Puigseslloses, Pol
dc.contributor.author
De Macedo, Morgane
dc.contributor.author
Lardeux, Virginie
dc.contributor.author
Pain, Stephanie
dc.contributor.author
Wang, Fu-Hua
dc.contributor.author
Källsten, Liselott
dc.contributor.author
Pubill, David
dc.contributor.author
Berzosa, Xavier
dc.contributor.author
Kehr, Jan
dc.contributor.author
Solinas, Marcello
dc.contributor.author
Camarasa, Jordi
dc.contributor.author
Escubedo, Elena
dc.contributor.author
López-Arnau, Raúl
dc.date.accessioned
2025-05-24T13:47:54Z
dc.date.available
2025-05-24T13:47:54Z
dc.date.issued
2025-07-01
dc.identifier.issn
1873-7064
dc.identifier.uri
http://hdl.handle.net/20.500.14342/5274
dc.description.abstract
Synthetic cathinones are emerging psychoactive substances designed to mimic the effects of classical psychostimulants. Among them, α-D2PV, a novel pyrrolidine-containing cathinone characterized by a phenyl group on the α-carbon atom, has gained significant attention. This study investigates the in vitro and in silico mechanism of action as well as the abuse liability of α-D2PV using rodent models. Dopamine (DA), noradrenaline (NE), and serotonin (5-HT) uptake inhibition assays were conducted in HEK293 cells expressing the corresponding human monoamine transporter, complemented by molecular docking studies at the DA transporter (DAT). Behavioral studies in male Swiss CD-1 mice assessed locomotor activity and conditioned place preference, while microdialysis and self-administration experiments were performed in male Sprague-Dawley rats. The findings reveal that α-D2PV is a potent DA and NE uptake inhibitor, with minimal activity at the 5-HT transporter (SERT). Docking studies showed that the benzene rings of α-PVP and α-D2PV align precisely in their most stable conformations at DAT. In vivo, α-D2PV elicited dose-dependent hyperlocomotion, thigmotaxis, and rewarding effects in mice, alongside increased extracellular DA levels in the nucleus accumbens of awake rats. Self-administration experiments confirmed α-D2PV's high reinforcing efficacy, indicating a significant risk of abuse in humans. Finally, these results underscore the necessity for continued surveillance of α-D2PV within the illicit drug market. Furthermore, novel synthetic cathinones incorporating a phenyl ring at the α-carbon side chain warrant proactive monitoring due to their potential to retain dopaminergic activity and evade initial legal controls.
dc.relation.ispartof
Neuropharmacology 2025, 272
dc.rights
Attribution 4.0 International
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
Synthetic cathinones
dc.subject
Self-administration
dc.title
Unveiling the potential abuse liability of α-D2PV: A novel α-carbon phenyl-substituted synthetic cathinone
dc.type
info:eu-repo/semantics/article
dc.description.version
info:eu-repo/semantics/publishedVersion
dc.relation.projectID
info:eu-repo/grantAgreement/MCI/PN I+D/PID2022-137541OB-I00
dc.relation.projectID
info:eu-repo/grantAgreement/SUR del DEC/SGR/2021 SGR 0090
dc.relation.projectID
info:eu-repo/grantAgreement/SUR del DEC/FI SDUR/2022 FISDU 00004
dc.identifier.doi
https://doi.org/10.1016/j.neuropharm.2025.110425
dc.rights.accessLevel
info:eu-repo/semantics/openAccess